Zhu CJ - Search Results

1

Reduction of Plasma MicroRNA-21 is Associated with Chemotherapeutic Response in Patients with Non-small Cell Lung Cancer.

Wei J, Liu LK, Gao W, Zhu CJ, Liu YQ, Cheng T, Shu YQ. Wei J, et al. Among authors: zhu cj. Chin J Cancer Res. 2011 Jun;23(2):123-8. doi: 10.1007/s11670-011-0123-2. Chin J Cancer Res. 2011. PMID: 23483517 Free PMC article.

2

Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer.

Wei J, Gao W, Zhu CJ, Liu YQ, Mei Z, Cheng T, Shu YQ. Wei J, et al. Among authors: zhu cj. Chin J Cancer. 2011 Jun;30(6):407-14. doi: 10.5732/cjc.010.10522. Chin J Cancer. 2011. PMID: 21627863 Free PMC article.

3

[Correlation between expression of forkhead box M1 (FOXM1) and clinicopathological features and prognosis in patients with non-small cell lung cancer (NSCLC)].

Liu YQ, Guo RH, Liu LK, Gao W, Zhu CJ, Wei J, Shu YQ. Liu YQ, et al. Among authors: zhu cj. Zhonghua Zhong Liu Za Zhi. 2011 Jun;33(6):426-30. Zhonghua Zhong Liu Za Zhi. 2011. PMID: 21875482 Chinese.

4

Plasminogen Activator Inhibitor 1 Promotes Immunosuppression in Human Non-Small Cell Lung Cancers by Enhancing TGF-Β1 Expression in Macrophage.

Zhu C, Shen H, Zhu L, Zhao F, Shu Y. Zhu C, et al. Cell Physiol Biochem. 2017;44(6):2201-2211. doi: 10.1159/000486025. Epub 2017 Dec 13. Cell Physiol Biochem. 2017. PMID: 29253845 Free article.

5

The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma.

Zhu C, Jiang L, Xu J, Ren A, Ju F, Shu Y. Zhu C, et al. Pathol Res Pract. 2020 Apr;216(4):152885. doi: 10.1016/j.prp.2020.152885. Epub 2020 Feb 13. Pathol Res Pract. 2020. PMID: 32113794

6

Heterogeneity of CTC contributes to the organotropism of breast cancer.

Yu T, Wang C, Xie M, Zhu C, Shu Y, Tang J, Guan X. Yu T, et al. Biomed Pharmacother. 2021 May;137:111314. doi: 10.1016/j.biopha.2021.111314. Epub 2021 Feb 12. Biomed Pharmacother. 2021. PMID: 33581649 Free article. Review.

7

Single-cell RNA sequencing reveals cell heterogeneity and transcriptome profile of breast cancer lymph node metastasis.

Xu K, Wang R, Xie H, Hu L, Wang C, Xu J, Zhu C, Liu Y, Gao F, Li X, Wang C, Huang J, Zhou W, Zhou G, Shu Y, Guan X. Xu K, et al. Oncogenesis. 2021 Oct 5;10(10):66. doi: 10.1038/s41389-021-00355-6. Oncogenesis. 2021. PMID: 34611125 Free PMC article.

8

Expression of CDK7 correlates with molecular subtypes and predicts clinical outcomes in breast cancer.

Tang L, Zhu C, Jin J, Wang X, Yu L, Guan X. Tang L, et al. Transl Cancer Res. 2021 Feb;10(2):669-680. doi: 10.21037/tcr-20-2911. Transl Cancer Res. 2021. PMID: 35116400 Free PMC article.

9

Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.

Li X, Tang L, Chen Q, Cheng X, Liu Y, Wang C, Zhu C, Xu K, Gao F, Huang J, Wang R, Guan X. Li X, et al. Chin Med J (Engl). 2022 Oct 20;135(20):2436-2445. doi: 10.1097/CM9.0000000000002329. Chin Med J (Engl). 2022. PMID: 36583862 Free PMC article.

10

Estrogen receptor beta suppresses the androgen receptor oncogenic effects in triple-negative breast cancer.

Xu F, Xu K, Fan L, Li X, Liu Y, Yang F, Zhu C, Guan X. Xu F, et al. Chin Med J (Engl). 2024 Feb 5;137(3):338-349. doi: 10.1097/CM9.0000000000002930. Epub 2023 Dec 15. Chin Med J (Engl). 2024. PMID: 38105538 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

146 results

Search Page

Filters